全文获取类型
收费全文 | 1083826篇 |
免费 | 87732篇 |
国内免费 | 2894篇 |
专业分类
耳鼻咽喉 | 15139篇 |
儿科学 | 30496篇 |
妇产科学 | 29352篇 |
基础医学 | 153294篇 |
口腔科学 | 29525篇 |
临床医学 | 97836篇 |
内科学 | 211628篇 |
皮肤病学 | 20118篇 |
神经病学 | 91623篇 |
特种医学 | 42734篇 |
外国民族医学 | 182篇 |
外科学 | 169758篇 |
综合类 | 27742篇 |
现状与发展 | 2篇 |
一般理论 | 566篇 |
预防医学 | 86250篇 |
眼科学 | 26304篇 |
药学 | 79863篇 |
6篇 | |
中国医学 | 1917篇 |
肿瘤学 | 60117篇 |
出版年
2021年 | 9819篇 |
2019年 | 9962篇 |
2018年 | 12614篇 |
2017年 | 9769篇 |
2016年 | 10926篇 |
2015年 | 12932篇 |
2014年 | 18751篇 |
2013年 | 27320篇 |
2012年 | 38629篇 |
2011年 | 40505篇 |
2010年 | 23204篇 |
2009年 | 21424篇 |
2008年 | 37258篇 |
2007年 | 39975篇 |
2006年 | 39729篇 |
2005年 | 39363篇 |
2004年 | 37870篇 |
2003年 | 36061篇 |
2002年 | 34286篇 |
2001年 | 37733篇 |
2000年 | 37925篇 |
1999年 | 32968篇 |
1998年 | 11918篇 |
1997年 | 10781篇 |
1996年 | 10422篇 |
1995年 | 9873篇 |
1994年 | 9265篇 |
1992年 | 27795篇 |
1991年 | 27143篇 |
1990年 | 26513篇 |
1989年 | 25567篇 |
1988年 | 24095篇 |
1987年 | 23722篇 |
1986年 | 22614篇 |
1985年 | 21968篇 |
1984年 | 17478篇 |
1983年 | 15026篇 |
1982年 | 10064篇 |
1981年 | 9351篇 |
1979年 | 17384篇 |
1978年 | 12770篇 |
1977年 | 10754篇 |
1976年 | 9862篇 |
1975年 | 10550篇 |
1974年 | 13065篇 |
1973年 | 12492篇 |
1972年 | 11837篇 |
1971年 | 10939篇 |
1970年 | 10444篇 |
1969年 | 10068篇 |
排序方式: 共有10000条查询结果,搜索用时 931 毫秒
991.
992.
993.
K. KARNICKI† R. D. MCBANE II † R. S. MILLER† R. J. Leadley JR ¶ J. MORSER W. G. OWEN†‡ J. H. CHESEBRO§ 《Journal of thrombosis and haemostasis》2004,2(12):2162-2169
BACKGROUND/OBJECTIVE: The efficacy of a direct factor (F)Xa inhibitor, ZK-807834, was compared with indirect inhibition by enoxaparin for inhibition and deaggregation of acute platelet-rich thrombi in a well-characterized porcine carotid injury model. METHODS: A crush injury was performed on a randomly chosen carotid artery and the thrombus allowed to propagate for 30 min. Pigs then received intravenous drug for 35 min: ZK-807834-Dose 1 (40 microg kg(-1) bolus + 1.5 microg kg(-1) min(-1) infusion, n=6); ZK-807834-Dose 2 (20 microg kg(-1) bolus + 0.75 microg kg(-1) min(-1) infusion; n=6); enoxaparin (1 mg kg(-1) bolus; n=6); or saline (n=6). Five minutes after drug initiation, the contralateral artery was injured. Thrombus size was monitored by scintillation detection of autologous 111In-platelets. RESULTS: The prothrombin time ratio was 2.2 +/- 0.1; 1.4 +/- 0.3; 1.2 +/- 0.9 and 1.1 +/- 0.2, respectively. ZK-807834-Dose 1 significantly inhibited carotid platelet deposition (525 +/- 226 x 10(6) cm(-2); P = 0.008), whereas ZK-807834-Dose 2 (2325 +/- 768) and enoxaparin (1236 +/- 383) were not different from saline (2776 +/- 642). Thrombus deaggregation was greatest for animals receiving ZK-807834-Dose 1 (473 +/- 185). Neither ZK-807834-Dose 2 (1588 +/- 480) nor enoxaparin (1618 +/- 686) was different from saline control (2222 +/- 598). CONCLUSIONS: Direct FXa inhibition with ZK-807834, at a prothrombin time ratio of 2.2, effectively inhibits thrombosis and promptly deaggregates thrombi induced by arterial injury. In contrast, indirect FXa inhibition with enoxaparin was ineffective. 相似文献
994.
995.
Mary C Tierney W Gary Snow Jocelyn Charles Rahim Moineddin Alex Kiss 《The American journal of geriatric psychiatry》2007,15(2):140-148
OBJECTIVE: The authors examined the accuracy of certain neuropsychological tests in the prediction of harm resulting from self-neglect in cognitively impaired seniors who lived alone. METHODS: The study included 130 participants, aged 65 and older, who scored less than 131 on the Dementia Rating Scale. Neuropsychological tests were administered at baseline, resulting in eight predictive scores. Informants and primary care physicians provided information about harm that occurred to the participants during the 18-month prospective follow up. An incident was defined as harmful if it occurred as the result of self-neglect or disorientation and resulted in physical injury or property loss or damage and required emergency interventions. Proportional hazard regression analysis was conducted to examine the predictive relationship between the eight neuropsychological tests and time to incident harm with age, sex, education, the Charlson Comorbidity Index, and the Mini-Mental State Examination included in the model as covariates. RESULTS: Twenty-seven participants experienced harm during the 18-month follow-up period. A proportional hazards model indicated that three neuropsychological tests, which measured recognition memory, executive functioning, and conceptualization, were independent risk factors for harm. CONCLUSIONS: These findings provide insight into why harm occurred in these cognitively impaired elders who lived alone. They also support the ecologic validity of these tests and suggest directions for the development of intervention strategies for harm prevention. 相似文献
996.
James W Wheless 《Neuropsychiatric Disease and Treatment》2007,3(4):409-421
Epilepsy is a common pediatric neurologic disorder that is difficult to manage in a substantial portion of children. Levetiracetam (LEV) is a novel antiepileptic drug (AED) that has recently been approved as add-on treatment for various seizure types in epilepsy populations that include children: for refractory partial seizures in epilepsy patients ≥4 years old, for myoclonic seizures in juvenile myoclonic epilepsy patients ≥12 years old, and for primary generalized tonic-clonic seizures in idiopathic generalized epilepsy patients (≥6 years old with FDA approval; ≥12 years old with EMEA approval). A review of published pediatric studies indicates that the efficacy of LEV is best established for partial seizures; however, results from recent double-blind and open-label trials indicate that adjunctive LEV also controls generalized seizures – particularly myoclonic and generalized tonic-clonic – in children and adolescents with primary generalized epilepsy. LEV was well-tolerated in pediatric studies. The most common adverse events (AEs) reported were sedation related. Behavioral AEs were among the most commonly reported events in some trials; conversely, improvements in behavior and cognition were also frequently reported. LEV appears to be a safe and effective AED with unique characteristics that benefit the treatment of children with epilepsy. 相似文献
997.
Sanjay Sisodiya J Helen Cross Ingmar Blümcke David Chadwick John Craig Peter B Crino Paul Debenham Norman Delanty Frances Elmslie Mark Gardiner Jeffrey Golden David Goldstein David A Greenberg Renzo Guerrini Michael Hanna John Harris Paul Harrison Michael R Johnson George Kirov Dimitri M Kullman Andrew Makoff Carla Marini Rima Nabbout Lina Nashef Jeffrey L Noebels Ruth Ottman Munir Pirmohamed Asla Pitk?nen Ingrid Scheffer Simon Shorvon Graeme Sills Nicholas Wood Sameer Zuberi 《Epileptic Disord》2007,9(2):194-236
The Sixth Epilepsy Research Foundation workshop, held in Oxford in March 2006, brought together basic scientists, geneticists, epidemiologists, statisticians, pharmacologists and clinicians to consider progress, issues and strategies for harnessing genetics to improve the understanding and treatment of the epilepsies. General principles were considered, including the fundamental importance of clear study design, adequate patient numbers, defi ned phenotypes, robust statistical data handling, and follow-up of genetic discoveries. Topics where some progress had been made were considered including chromosomal abnormalities, neurodevelopment, hippocampal sclerosis, juvenile myoclonic epilepsy, focal cortical dysplasia and pharmacogenetics. The ethical aspects of epilepsy genetics were reviewed. Principles and limitations of collaboration were discussed. Presentations and their matched discussions are produced here. There was optimism that further genetic research in epilepsy was not only feasible, but might lead to improvements in the lives of people with epilepsy. 相似文献
998.
M. J. Fritsch M. Bauer C. J. Partsch W. G. Sippell H. M. Mehdorn 《Child's nervous system》2007,23(6):627-631
Objective Endoscopic third ventriculostomy (ETV) is a standard procedure for the treatment of obstructive hydrocephalus in children.
Main part of the procedure is the perforation of the third ventricle floor (tuber cinereum). This structure is part of the
hypothalamic–pituitary neuronal network of cerebral endocrine regulation. There are no systematic data available about the
endocrine status after ETV in children.
Materials and methods We examined 20 children who had undergone ETV. Examination included laboratory tests (adrenocorticotropic hormone, prolactin,
insulin-like growth factor 1 [IGF-1], IGF-binding protein 3 [IGFBP-3], fT3, fT4, thyroid-stimulating hormone [TSH], serum
osmolarity, electrolytes, glucose, urea, follicle-stimulating hormone [FSH] and luteinizing hormone [LH], and testosterone
in selected patients), measurement of weight, height, and head circumference, and physical examination. The study was approved
by the Ethics Committee of the Medical Faculty of Kiel University.
Results In seven patients, prolactin was moderately elevated. One patient demonstrated a significantly increased prolactin (56.3 ng/ml).
In all eight patients, this was the only laboratory value that was out of the normal range; all other parameters were normal.
Three other patients showed one abnormal parameter (decrease in FSH and LH, increase in TSH, decrease in IGF-1 and IGFBP-3).
In nine patients, weight or height was not within the 3rd to 97th centiles for age.
Discussion and conclusion More patients than expected demonstrated endocrine laboratory abnormalities. However, there was no clinical relevance in any
of the studied patients. It remains inconclusive whether ETV contributes to the abnormalities of prolactin levels or to other
endocrine parameters in pediatric patients. Longitudinal studies are necessary to delineate the effect of ETV on endocrine
regulation.
Presented at the Third World Conference of the International Study Group on Neuroendoscopy (ISGNE), Marburg, Germany, 15–18
June 2005. 相似文献
999.
Paul J Huggan David R Murdoch 《Clinical infectious diseases》2007,45(12):1647-8; author reply 1649-51
1000.